Newly public genetic information company Invitae has dropped prices for its genetic tests, just as the NIH says it will launch a study of the efficacy of cancer drugs by genetic mutation. Both are a testament to the rapidly evolving role of genetic information in patient treatment.
A Singapore-led clinical group has published a study of a novel approach to investigating how genes affect options to treat liver cancer, highlighting the city-state's growing role in oncology research.
Royal Philips and the Massachusetts Institute of Technology (MIT) have partnered in a 5-year research alliance with a $25 million budget to develop novel product solutions in healthcare and lighting.
Express Scripts has been warning about a crackdown on cancer drug spending. Now, it's talking about how.
Roche's Ventana Medical Systems announced a companion diagnostic agreement centered around Astellas Pharma's cancer fighting ASP5878.
Roche snatched up genomics research outfit CAPP Medical to get its hands on the company's cancer detection platform, continuing its M&A streak and strengthening its foothold in cancer R&D.
Australia's reimbursement agency has lagged developed country counterparts in paying for newly approved new cancer therapies, highlighting problems at the tail end of a system that patients and industry complain is broken.
New Zealand researchers say they may have discovered a route for drugs to be more effective against genetic stomach and lobular breast cancers in their early stages.
Japan's Eisai sold the worldwide rights, excluding Japan, to Phase I/II cancer candidate EP-6438 to U.S.-based Epizyme for $40 million upfront, revising a 2011 agreement on discovery, development and commercialization of a therapy aimed at non-Hodgkin B-cell lymphoma and other cancers.
Amgen just announced the debut of the Neulasta Delivery Kit to automatically deliver the medication for infection prevention among cancer patients about 27 hours after chemotherapy, thereby ensuring compliance with the dosing instructions.